ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

BiotechTV - News

Por: BiotechTV

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

343 episodios disponibles

Latest episodes of the podcast BiotechTV - News

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more 12/01/2026

SF Healthcare Week: Flagship Pioneering's Founder Noubar Afeyan shares his thoughts on the image of science in the United States today, biotech's roller coaster 2025, mRNA, AI, and more 12/01/2026

SF Healthcare Week: Baird Senior Analyst Brian Skorney comments on Monday's conference news and highlights his top picks ahead for 2026 12/01/2026

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy 12/01/2026

SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy 12/01/2026

SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year 12/01/2026

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year 07/01/2026

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026 30/12/2025

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza 29/12/2025

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation 09/12/2025

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week 09/12/2025

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftcoclax, which was recently approved in China and is in multiple global registration studies 09/12/2025

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know 09/12/2025

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I 08/12/2025

ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS 08/12/2025

ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting 08/12/2025

ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies. 08/12/2025

ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma 08/12/2025

Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH 08/12/2025

ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS 07/12/2025

1 2 3 ... 18 Siguiente › Última »